Comparative Claims In Product Promotions: FDA Isn’t Entirely Leaving It To Firms To ‘Duke It Out’

Four years after Woodcock’s famous comments, OPDP notes it is evaluating comparative claims as indicated in a recent untitled letter. DOJ is also looking at comparative claims. New FDA guidances are in the works, but it remains unknown when they will issue.

Drug comparison
US FDA is looking at drug promotions with comparative claims • Source: Shutterstock

Catherine Gray, director of the US Food and Drug Administration’s Office of Prescription Drug Promotion, cleared up a question some sponsors have about comparative claims in product advertisements when she noted that the agency is, in fact, paying attention to them.

During the Food and Drug Law Institute’s 13-14 October conference on advertising & promotion for medical products, a panel moderator alluded to a comment FDA’s Janet Woodcock made a few years ago

More from Marketing & Advertising

More from Compliance